Next Article in Journal
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
Next Article in Special Issue
The β-Secretase 1 Enzyme as a Novel Therapeutic Target for Prostate Cancer
Previous Article in Journal
Multi-Institutional Evaluation of Pathologists’ Assessment Compared to Immunoscore
Previous Article in Special Issue
Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 16
10.3390/cancers15164046
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity

by
Shira Toledano
and
Gera Neufeld
*
The Cancer Research Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109602, Israel
*
Author to whom correspondence should be addressed.
Cancers 2023, 15(16), 4046; https://doi.org/10.3390/cancers15164046
Submission received: 27 June 2023 / Revised: 24 July 2023 / Accepted: 28 July 2023 / Published: 10 August 2023
(This article belongs to the Special Issue The Biological Mechanism of Cancer Proliferation and Metastasis)
Browse Figures
Review Reports Versions Notes

Abstract

:

Simple Summary

Cancer is the second leading cause of death in the US. In 2023, approximately 609,820 deaths from cancer are expected. Plexins are a family of receptors that directly affect tumor cell invasiveness and proliferation and, as a result, promote or inhibit tumor progression and, as such, may also serve as potential biomarkers for various types of cancer. The main ligands of the plexin family of receptors are semaphorins. Here, we review only the direct effects of plexins-mediated signal transduction on the behavior of various types of tumor cells, excluding their effects on the various other types of cells that are recruited to the tumor microenvironment. Plexins also transduce the signals of additional ligands and associate with various cell membrane-bound and intracellular modulators that, in turn, modify their effects.

Abstract

Plexins are a family of nine single-pass transmembrane receptors with a conserved GTPase activating protein (GAP) domain. The plexin family is divided into four subfamilies: Type-A, type-B, type-C, and type-D plexins. Plexins function as receptors for axon guidance factors of the semaphorin family. The semaphorin gene family contains 22 genes that are divided into eight subclasses of which subclasses three to seven represent vertebrate semaphorins. The plexins and their semaphorin ligands have important roles as regulators of angiogenesis, cancer proliferation, and metastasis. Class 3 semaphorins, with the exception of sema3E, are the only semaphorins that do not bind directly to plexins. In order to transduce their signals, they bind instead to complexes consisting of receptors of the neuropilin family and various plexins. Some plexins also form complexes with tyrosine-kinase receptors such as the epidermal growth factor receptor ErbB2, the mesenchymal epithelial transition factor receptor (MET), and the Vascular endothelial growth factor receptor 2 (VEGFR2) and, as a result, can modulate cell proliferation and tumor progression. This review focuses on the roles of the different plexins in the control of cancer cell proliferation and invasiveness. Plexins also affect tumor progression and tumor metastasis by indirect mechanisms, such as modulation of angiogenesis and immune responses. However, these topics are not covered in the present review.

1. The Plexin Receptor Family

The nine receptors of the plexin family are segregated into four subfamilies consisting of four Type-A plexins, three Type-B plexins, and single C and D plexins (Figure 1) [1]. Plexins serve as direct binding receptors for most semaphorins, which are a large family of evolutionarily conserved signaling molecules that were initially identified as axon guidance factors [2]. The extracellular domains of all plexins contain a sema domain which is also present in semaphorins and serves as an auto-inhibitory domain in the basal, dimeric, non-activated state of the receptor [3]. Once a semaphorin binds to the extracellular domain of the plexins, it induces a conformational change in the two dimerized plexins that initiates signal transduction [3,4,5]. The extracellular domains of the plexins and of the semaphorins also contain plexin-semaphorin-integrin (PSI) domains which contain eight cysteine residues and bridge the sema and immunoglobulin-plexin-transcription (IPT) domains thereby ensuring the correct formation and correct orientation of the ligand-receptor binding sites [1]. The extracellular domain of the plexin-B family receptors is unique among the plexins because it contains a conserved cleavage site for furin-like pro-protein convertases. This cleavage site is posttranslationally processed, resulting in the generation of functional soluble type B plexin extracellular domains that are able to sequester semaphorins that bind to type B plexins [6]. The intracellular domains of the plexins are characterized by the presence of a GTPase-activating (GAP) domain. The GAP domain is highly conserved throughout the plexin family. Activation of plexin signal transduction is associated with the recruitment and activation of several GTP-binding proteins, such as Rac1, Rnd1, and Rho, to the GAP domain [7]. Activation of the GAP domain also confers the deactivation of R-Ras, M-Ras, and Rap1 in all plexins [8,9,10,11]. The GAP activity toward R-Ras and M-Ras, but not toward Rap1, also requires Rnd GTPases binding to the plexin receptors [8,9,11,12]. The intracellular domains also contain putative tyrosine phosphorylation sites and a split cytoplasmic SP (sex-plexin) domain but no tyrosine kinase domain (Figure 1) [13].
Plexin-A1 is the best-studied plexin among the vertebrate type-A plexins. Its cytoplasmatic domain was found to be critical for its ability to mediate sema3A signal transduction [13,14,15]. Following stimulation by sema3A, the Rac1 guanyl nucleotide exchange factor (GEF) FARP2 and Rac1 bind to plexin-A1, resulting in the activation of Rac1, which subsequently promotes WNT3A-induced accumulation of β-catenin in the nucleus [16]. Active Rac1 also binds to the RhoGTPase Binding Domain (RBD) of plexin-A1 and, as a result, induces a conformational change in the intracellular domain of plexA1, which enables the binding of Rnd1 to plexin-A1. Interestingly, RhoD is also able to bind to the RBD domain and can inhibit the binding of Rnd1 [17,18]. Type-A plexins also interact directly with Molecules Interacting with CasL (MICALs). The three MICAL human family members are flavoprotein oxidoreductases that oxidize actin filaments in response to stimulation with semaphorins causing their disassembly [19].
In contrast to type-A plexins, type-B plexins contain a unique C-terminal PDZ binding motif [20]. Through this domain type-B plexins associate with PDZ-RhoGEF and with Leukemia-associated RhoGEF (LARG). Rnd1 promotes this association by binding to plexin-B1 [21]. It was also found that activation of plexin-B1 by sema4D creates docking sites for the SH2 domains of phospholipase C-gamma (PLCgamma). Recruited PLCgamma subsequently then activates PDZ-RhoGEF [22]. The PDZ binding motif is also critical for the activation of the plexin-B family by RhoA, resulting in stress fiber formation [23]. Another regulator of Rho activity is p190 Rho-GTPase, which inactivates Rho upon the binding of semaphorins to plexins [24]. Unlike the type-A and Type-C plexins, plexin-D1 also possesses a PDZ binding motif [25].
Type-A and Type-B plexins associate spontaneously to form homodimers [4,5] or heterodimers [26]. Class 4–7 semaphorins bind directly to plexins. Class-3 semaphorins, with the exception of sema3E which binds directly to plexin-D1, bind to a complex consisting of a plexin receptor, and one of the two neuropilin receptors that on their own do not transduce semaphorin signals [13,27].
Type-B plexins were reported to associate with the tyrosine-kinase receptor MET [28]. Sema4D binds to plexin-B1 and plexin-B2 receptors, and it was observed that when plexin-B1 is associated with the MET receptor and with its close homolog receptor Ron, sema4D induces their auto-phosphorylation and promotes invasiveness of tumor cells expressing these receptors as well as tumor angiogenesis [29,30]. Likewise, it was found that sema3C can also transactivate several tyrosine-kinase receptors, including EGFR, ErbB2, and MET [31]. Plexins can also form complexes with the vascular endothelial growth factor (VEGF) tyrosine-kinase receptor VEGFR2. In the presence of sema6D, plexin-A1 receptors associate with VEGFR2 and promote the proliferation of malignant mesothelioma cells [32]. Additionally, it was discovered that plexin-A4 can also associate with VEGFR2 and with the fibroblast growth factor tyrosine-kinase receptor FGFR1. This, in turn, enhanced the VEGF- and FGF-induced phosphorylation of these tyrosine-kinase receptors [26]. Plexins are also able to associate with the epidermal growth factor receptor ErbB2. ErbB2 can promote pro-migratory and angiogenesis effects by activation and phosphorylation of plexin-B1 and, as a result, activation of RhoA via RhoGEF [22,33]. Additionally, it was reported that sema3E induces invasiveness and metastatic spreading of tumor cells through the transactivation of ErbB2 by a post-translationally modified sema3E that was truncated by furin-like pro-protein convertases (P61-sema3E). In contrast to full-length sema3E, p61-Sema3E induces the association of plexin-D1 with ErbB2 and the phosphorylation of ErbB2 and, as a result, induced tumor cell metastasis [34,35]. Plexins also associate with additional cytoplasmic tyrosine kinases, except from VEGFR2 and ErbB2, such as FES, SRC, PYK2, and FYN [36].
In this review, we focus on the effects that signal transduction mediated by the receptors of the plexin receptor family has on the proliferation, migration, and invasiveness of tumor cells. Signal transduction by plexin receptors also modulates the behavior of non-transformed cells recruited into the tumor microenvironment, such as endothelial cells and various types of immune cells. We do not cover these topics in this review as they are covered elsewhere [37,38,39,40].

2. The Role of the Different Plexins in Tumor Progression

2.1. Type-A Plexins

Class-3 semaphorins transduce repulsive signals using complexes of neuropilin and type-A plexin receptors. Activation of these plexins by class-3 semaphorins as well as by class-6 semaphorins usually inhibits tumor angiogenesis, and when expressed in tumor cells, these plexins also usually inhibit tumor progression. However, this is a generalization, and their association with additional modulators can lead to opposite effects.

2.1.1. Plexin-A1

Plexin-A1, along with plexin-A4, is a major transducer of sema3A signals when associated with neuropilin-1 (NRP1) [26,41,42]. While plexin-A1 clearly conveys sema3A-induced anti-angiogenic signals [43,44], the effects of plexin-A1 transduced sema3A signals on tumor cells are not as clear. Plexin-A1 was reported to convey sema3A inhibitory signals in malignant mesothelial cells inhibiting their proliferation (Figure 2) (Table 1) [45].
In contrast, it was reported that perlecan interacts with a complex of sema3A, plexin-A1, and NRP-1 on the cell surface of prostate cancer cells and that cleavage of this complex by MMP-7 cell-cell bonds promotes the metastatic dissemination of prostate cancer cells (Table 1) (Figure 3) [46]. Plexin-A1 expression was found to be significantly downregulated in sections from tissues of invasive human breast cancer [47]. It was also reported that plexin-A1 can form a complex with VEGFR2 in malignant pleural mesothelioma cells. Sema6D binds to plexin-A1 and promotes the phosphorylation of VEGFR2. As a result, sema6D activates NF-KB and mediates survival and tumor growth (Table 1) (Figure 3) [32].
Table 1. Plexins and their role in various types of cancers. Shown is a summary of the effects of the various plexins and of their various ligands and associated cell surface molecules, on the behavior of various types of tumor cells.
Table 1. Plexins and their role in various types of cancers. Shown is a summary of the effects of the various plexins and of their various ligands and associated cell surface molecules, on the behavior of various types of tumor cells.
PlexinModulators of Plexin-Mediated Signal TransductionRoleCancer TypeRefs
Plexin-A1Sema3AInhibition of
proliferation		Malignant
mesothelial cells		[45]
Sema3A,
NRP-1, Perlecan		Promotion of
metastatic
dissemination		Prostate cancer cells[46]
Sema6D, VEGFR-2Promotion of survival and tumor growthMalignant
mesothelioma cells		[32]
Sema3APromotion of
proliferation and
glycolytic activity		Lung cancer cells[48]
Sema3A, NRP-1Inhibition of
proliferation		Brain tumor stem cells[49]
Plexin-A2 Enhancement of
migration and invasion		Prostate cancer cells[50]
Sema3C, NRP-1, MAOA, METPromotion of
perineural invasion		Prostate cancer cells[51]
Sema3A, KIAA1199Inhibition of apoptosisCervical cancer cells[52]
Enabling cell
proliferation and the development of tumors 		Glioblastoma
derived cells		[53]
Plexin-A3 Inhibition of cell
invasion		Epithelial ovarian cancer cells [54]
Plexin-A4Sema6BPromotion of pro-
proliferative signals		Glioblastoma-derived cells, lung-cancer-derived cells, malignant-melanoma-derived cells[26]
miR-564Promotion of cell
proliferation and
migration		Non-small cell lung carcinoma cells[55]
Plexin-B1Sema4DPromotion of EMT and tumor cell metastasisHead and neck
squamous cell
carcinoma		[56]
Sema4DPromotion of cell
invasion, proliferation, and migration		Osteosarcoma cells[57]
Sema3C,
NRP-1/2, EGFR, ErbB2, MET		Promotion of cancer growthCastration-resistant prostate cancer cells[31]
TMPRSS2-ERGPromotion of cell
migration and invasion		Prostate cancer cells[58]
Promotion of cell
migration and invasion		Ovarian cancer
derived cells		[59]
Inhibition of breast cancer cell motilityBreast cancer cells[60]
Suppression of
tumorigenesis		Primary melanoma cells[61]
Inhibition of cell
proliferation		Basal cell carcinoma cells[62]
Plexin-B2 Inhibition of cell
proliferation		Basal cell carcinoma cells[62]
Sema4C, ErbB2Promotion of
proliferation and
development of tumor metastasis		Breast cancer
derived cells		[63]
Sema4C, METPromotion of glioma and glioblastoma cell invasionGlioma and
Glioblastoma cells		[64]
AngiogeninInhibition of tumor cell proliferation and
inhibition of tumor
development		Glioblastoma cells, breast cancer cells, and myelogenous leukemia cells[65]
AngiogeninEnhancement of CSC stemness and resistance to chemotherapyProstate cancer stem cells[66]
AngiogeninPromotion of
proliferation, invasion, and tumor growth		Glioblastoma cells[67]
Circular RNA, Circ_0013958Promotion of
proliferation,
migration, invasion, and tumor growth		Ovarian cancer cells[68]
EGFRPromotion of
proliferation,
invasiveness and tumor-forming ability by
constitutively active plexin-B2		Stem cells from
cancers from
unknown primary tumors		[69]
Plexin-B3Sema5AInhibition of migration and invasionGlioma cells[70]
Inhibition of migration, invasion, and tumor metastasisPancreatic cancer cells[71]
Promotion of cancer cell growth, cell
migration, cell invasion, and tumor progression		Triple-negative breast cancer cells[72]
Plexin-C1Sema7AInhibition of tumor progressionMelanoma cells[73]
Inhibition of tumor progressionGlioma cells[74]
Sema7A,
β1 integrin
receptors		Promotion of
metastasis		Melanoma and breast cancer cells[75]
Promotion of migration and proliferationGastric cancer cells[76]
Plexin-D1P61-sema3E, ErbB2Promotion of tumor cell invasiveness and tumor cell metastasisMelanoma cells, lung carcinoma cells, colon
carcinoma cells		[34,35]
NR4A1Promotion of apoptosisBreast cancer cells[77]
Sema3C, plexin-A2, NRP-1Promotion of cell
survival		Glioma stem cells[78]
Additionally, although sema3A usually functions as a tumor suppressor, it was discovered that plexin-A1 can mediate sema3A oncogenic signals in lung cancer cells. Inhibition of plexin-A1 decreased cell proliferation in these tumor cells and suppressed their glycolytic activity (Table 1) [48]. Sema3A-mediated Plexin-A1/NRP-1-mediated signal transduction was also found to inhibit the proliferation of brain tumor stem cells. Surprisingly, sema3A nevertheless concomitantly promoted the invasive activity of these cells (Figure 2) (Table 1) [49].

2.1.2. Plexin-A2

Plexin-A2 transduces signals of class-3 semaphorins, such as sema3B. Plexin-A2 mRNA expression decreased in mouse genetic models of tumor progression, such as the RipTag2 model [79,80]. Plexin-A2 is the main plexin receptor that binds to NRP-1 and NRP-2 and transduces sema3B signals in association with plexin-A4 [42]. Sema3B is a tumor suppressor gene. Its expression is lost in lung cancer, liver cancer, and neuroblastoma [81,82,83]. Plexin-A2 expression was upregulated in metastatic prostate cancer tumors. In contrast to the above-mentioned studies, plexin-A2 upregulation enhanced the migration and invasion of prostate cancer cells (Table 1) [50]. Plexin-A2 expression was also upregulated in glioblastomas [78]. An in-silico study identified plexin-A2 as a gene that is never mutated in malignant melanomas and may thus be essential for malignant melanoma development and tumor progression [84]. The expression of sema3C, NRP-1, and plexin-A2 is upregulated by monoamine oxidase A (MAOA) in prostate cancer cells. The produced sema3C then binds to NRP-1, which induces the formation of a signaling complex containing NRP-1, plexin-A2, and the MET tyrosine-kinase receptor. This, in turn, activates MET-mediated signal transduction and induces perineural invasion by prostate cancer cells (Table 1) (Figure 3) [51].
KIAA1199 was identified as BCL-3 and p65 expression-dependent gene in transformed keratinocytes. Its expression is enhanced following human papillomavirus (HPV) infection of keratinocytes. Interestingly, KIAA1199 also binds to the intracellular domain of plexin-A2 and inhibits sema3A-induced apoptosis of cervical cancer cells (Table 1) (Figure 3) [52]. Plexin-A2 was also found to enable the development of tumors from glioblastoma-derived cells. Knock-out of plexin-A2 in these cells inhibited their proliferation and induced senescence and cell cycle arrest. The intracellular domain of plexin-A2 was found to be essential for these pro-proliferative effects. Re-expression of plexin-A2 mutated in its semaphorin binding domain in plexin-A2 knock-out glioblastoma-derived cells did not abrogate rescue of cell proliferation, suggesting that the pro-proliferative effect of plexin-A2 is not activated by the binding of a semaphorin to plexin-A2 (Table 1) [53].

2.1.3. Plexin-A3

Plexin-A3 forms complexes with NRP1 and NRP2 and transduces the repulsive signal of sema3F and sema3A [85,86,87,88]. Sema3F is an inhibitor of tumor angiogenesis and tumor lymph angiogenesis [89,90] and inhibits lymph vessels-mediated metastasis of head and neck squamous carcinoma cells [88]. Over-expression of plexin-A3 was found to inhibit cell invasion of epithelial ovarian cancer cells (Table 1) [54].

2.1.4. Plexin-A4

Plexin-A4 transduces signals of class 3 semaphorins such as sema3A and 3B [26,42,44] and of class-6 semaphorins [42,91,92]. Plexin-A4 in association with plexin-A1 transduces inhibitory signals of sema3A in U87MG glioblastoma cells. In addition, plexin-A4 transduces pro-proliferative signals induced by sema6B in glioblastoma cells. The development of tumors in athymic nude mice from implanted U87MG glioblastoma cells in which plexin-A4 or sema6B expression was silenced is strongly inhibited. Likewise, silencing the expression of plexin-A4 in various lung cancer-derived cells or in malignant melanoma-derived cells also inhibited the proliferation of these cells (Table 1) (Figure 3) [26]. Additionally, in non-small cell lung carcinoma cells, inhibition of plexin-A4 expression using microRNA (miR)-564 inhibited the proliferation and migration of these cells (Table 1) [55]. Plexin-A4 was also found to function as a negative regulator of Cytotoxic T-cell migration and proliferation, independently of semaphorins. It was more abundant in circulating Cytotoxic T-cell in melanoma patients as compared with healthy volunteers [93]. Plexin-A4 (or plexin-A1) in a complex with NRP-1 can transduce sema3A attractive signals involving VEGFR1 for tumor-associated macrophages after hypoxia induction. Once tumor-associated macrophages are in the hypoxic areas of the tumor, they remain there because of plexinA4/plexin-A1 signals. As a result, tumor-associated macrophages lose their anti-tumor immunity and promote angiogenesis, tumor growth, and metastasis [44].

2.2. Type-B Plexins

Type-B plexins are known to participate in the promotion of angiogenesis and tumor progression. They transduce the signals of class-3, class-4, and class-5 semaphorins and of other factors, such as the ribonuclease angiogenin [65] and the androgen-regulated-trans-membrane-serine protease gene [58].

2.2.1. Plexin-B1

Plexin-B1 transduces signals of sema4D (also known as CD100) in head and neck squamous cell carcinoma (HNSCC) in a xenograft mouse model [56]. The soluble cleaved form of sema4D was found to promote epithelial-mesenchymal transition (EMT) and, consequently, tumor cells metastasis via plexin-B1 (Table 1) (Figure 3) [56]. In Osteosarcoma cells, sema4D-induced plexin-B1 signaling activates the Pyk2-PI3K/AKT pathway and promotes cell invasion, proliferation, and migration (Table 1) (Figure 3) [57]. In castration-resistant prostate cancer, plexin-B1 was observed to transduce the signals of sema3C together with NRP-1/2 and promote cancer growth by activation of EGFR, ErbB2, and MET (Table 1) (Figure 3) [31]. The TMPRSS2-ERG fusion gene was found to enhance the expression of plexin-B1 in prostate cancer cells. The upregulated plexin-B1 was observed to enhance TMPRSS2-ERG induced prostate cancer-derived VCaP cell migration and invasion (Table 1) [58]. In ovarian cancer, plexin-B1 was found to be upregulated in tumor tissues of patients as compared with healthy ovaries and to be in correlation with lymphatic metastasis. Knockdown of plexin-B1 in ovarian cancer-derived cells results in inhibition of AKT phosphorylation, re-arrangement of the actin cytoskeleton, and inhibition of tumor cell migration and invasion (Table 1) [59].
Opposite results were reported in a study that examined the role of plexin-B1 in breast cancer metastasis. In that study, knockdown of plexin B1 in MDA-MB-231 cells led to a remarkable increase in the motility of breast cancer cells (Table 1) [60]. Plexin-B1 was also found to function as a tumor suppressor gene in primary melanoma harboring an activated Raf oncogene. The ability of plexin-B1 to suppress tumorigenesis depended on its GAP domain (Table 1) [61]. Additionally, plexin-B1 and plexin-B2 were also found to function as tumor suppressors in basal cell carcinoma. Inhibition of the expression of these two plexins in these cells resulted in increased cell proliferation and elevation of nuclear YAP activity. Loss of plexin-B1/plexin-B2 could represent a mechanistic basis for the loss of contact inhibition, a hallmark of cancer (Table 1) [62].

2.2.2. Plexin-B2

Plexin-B2 functions as a receptor for the four class-4 semaphorins. Sema4C was found to promote the proliferation of breast cancer cells, and its expression in breast cancer is correlated with poor prognosis. Knock-down of either plexin-B2 or sema4C leads to cell cycle arrest, senescence, and cytokinesis defects in breast cancer-derived cells. Following sema4C binding, plexin-B2 was found to associate with ErbB2 and to activate PDZ-RhoGEF/LARG, an exchange factor for RhoA. Activation of RhoA was found to be critical for the proliferation and development of estrogen-independent tumor metastasis in mice (Table 1) (Figure 3) [63]. Plexin-B2 also transduces sema4C signals in glioblastoma cells. This, in turn, was found to be dependent on its GAP domain leading to the activation of RhoA and Rac1, promoting glioma and glioblastoma cell invasiveness [64,94]. Activation of plexin-B2 with sema4C also acts synergistically with HGF-activated MET to promote MET phosphorylation and to promote the progression of glioblastoma (Table 1) (Figure 3) [64].
Interestingly, plexin-B2 also functions as a receptor for angiogenin (ANG) [65], a secreted ribonuclease [95]. Plexin-B2 was found to mediate ANG stimulation of rRNA transcription, ANG-induced phosphorylation of AKT and ERK, and the resulting proliferation of tumor cells. Targeting the ANG-binding site of plexin-B2 with antibodies results in inhibition of the development of xenograft tumors in mice (Table 1) [65]. In prostate cancer, plexin-B2 plays a role together with angiogenin in the regulation of the stemness of prostate cancer stem cells (CSC). Inhibition of ANG and Plexin-B2 reduced CSC stemness and elicited CSC exhaustion. Inhibitors of angiogenin/plexin-B2 were also found to sensitize prostate CSCs to chemotherapy (Table 1) (Figure 3) [66]. Plexin-B2 was also found to promote glioblastoma progression induced by ANG/plexin-B2. Inhibition of either plexin-B2 or ANG was found to inhibit glioblastoma cell proliferation, invasion, and tumor growth in animal models (Table 1) (Figure 3) [67].
In ovarian cancer biopsies, plexin-B2 was upregulated together with the circular RNA, circ_0013958. Circ_0013958 prevents plexin-B2 downregulation by miR-637 and, as a result, promotes cell proliferation, migration, invasion, and tumor growth (Table 1) [68]. In stem cells from cancers of unknown primary tumors, plexin-B2 that was mutated in its extracellular IPT domain (G842C) is constitutively active, promoting their ability to proliferate and their tumor-forming ability. Mutated plexin-B2 also promotes the invasiveness of these stem cells via association with and activation of EGFR (Table 1) [69].

2.2.3. Plexin-B3

Plexin-B3 was found to transduce inhibitory signals of sema5A in glioma cells. It was found to inhibit glioma cell invasion and migration by induction of Rac1 inactivation (Figure 2). Furthermore, plexin-B3 activated by sema5A interacts with protein kinase C, which induces disassembly of actin stress fibers and phosphorylate actin-binding protein fascin-1. Fascin-1 and glial fibrillary acidic protein, GFAP, which is upregulated by sema5A, induce morphological changes in glioma cells and astrocytic differentiation of gliomas (Table 1) [70]. Additionally, plexin-B3 knockdown was found to promote the migration and invasion of pancreatic cancer cells and to induce tumor metastasis in mouse models (Table 1) [71]. Loss of plexin-B3 expression was also in correlation with worse prognosis in hepatocellular carcinoma patients [96]. In contrast, in triple-negative breast cancer cells, plexin-B3 knockdown inhibited cancer cell growth and cell migration and invasion, as well as tumor progression in animal models (Table 1) [72].

2.3. Plexin-C1

Plexin-C1 functions as a receptor for sema7A [97]. It is a tumor suppressor that inhibits progression of melanomas. Plexin-C1 expression is downregulated in primary malignant melanoma as compared with melanocytic nevi and is lowest in metastatic melanoma. Sema7A binding to plexin-C1 upregulates Lim kinase II, which phosphorylates cofilin and inactivates cofilin, which inhibits tumor progression (Figure 2) (Table 1) [73]. In human glioma cells, it was observed that Growth Arrest-Specific 5 (GAS5) is a tumor suppressor which downregulates miR-222 and, as a result, upregulates plexin-C1 and inactivates cofilin, resulting in inhibition of tumor progression (Table 1) [74]. The binding of sema7A to plexin-C1 and β1 integrin receptors stimulates the expression of the Chi3l1 gene, which promotes metastasis of melanoma and breast cancer cells (Table 1) [75]. In hepatocellular carcinoma (HCC), plexin-C1 was overexpressed. The expression was correlated with the histological grade of HCC and overall survival [98,99]. Plexin-C1 was also found to be upregulated in tumors of patients with stomach adenocarcinoma as compared to non-tumor tissues. In these tumors, it was found that plexin-C1 expression is regulated by interferon regulatory factor-5 (IRF5) and that the expression is highly correlated with the presence of M2 macrophages which promote tumor progression [100,101]. In gastric cancer cells, plexin-C1 was found to be upregulated and to promote migration and proliferation of these cells through activation of epithelial to mesenchymal transition (EMT) and through induction of the expression of genes related to inflammation (Table 1) [76]. Additionally, plexin-C1 is over-expressed in hepatocellular carcinoma, and its expression is inversely correlated with overall survival [99].

2.4. Plexin-D1

Plexin-D1 is expressed aberrantly in many types of solid tumors in both tumor vessels and tumor cells [102,103]. Plexin-D1 functions as a receptor for sema3E. In contrast to other class-3 semaphorins, sema3E binds to plexin-D1 directly without the requirement for neuropilins [104]. Sema3C binds to NRP-1, which then associates with plexin-D1 in endothelial cells to activate plexin-D1, resulting in inhibition of angiogenesis [105]. Interestingly, sema3C can also activate plexin-D1-mediated signal transduction in the absence of neuropilins, provided that plexin-A4 is also co-expressed along with plexin-D1 [106]. Sema3C was also reported to activate signaling via an NRP-2/plexin-A1 complex in lymphatic endothelial cells and to inhibit lymphangiogenesis [107]. Plexin-D1 mediates inhibitory signals induced by full-length sema3E to inhibit tumor angiogenesis and tumor metastasis [35]. Sema3E is cleaved by furin-like pro-protein convertases, which are abundant in the microenvironment of tumors, to produce p61-Sema3E, a cleaved active variant of sema3E [108]. The p61-sema3E cleavage product is also able to bind to plexin-D1 and to inhibit angiogenesis, but in contrast to the full-length form also promotes the association of plexin-D1 with ErbB2. This results in the activation of ErbB2 that, in turn, promotes tumor cell invasiveness and tumor metastasis (Table 1) (Figure 3) [34,35]. Plexin-D1 expressed in breast cancer cells interacts, in the absence of sema3E, with the orphan nuclear receptor NR4A1 to induce apoptosis. Following the binding of sema3E, the interaction with NR4A1 is disrupted, enabling sema3E-induced tumor cell survival. However, it is not clear if this effect is mediated by full length or by the furin-cleaved p61-Sema3E form of sema3E (Figure 2) (Table 1) [77]. Plexin-D1 was also found to form complexes with plexin-A2 and NRP-1. Sema3C signaling via this complex promotes the survival of glioma stem cells via activation of Rac1 (Table 1) (Figure 3) [78]. Plexin-D1 may serve as a potential biomarker for cervical cancer, as it was found that it is strongly expressed in the endothelial cells of the cervical cancer samples, and there is no expression of plexin-D1 in endothelial cells derived from normal cervical tissues [109].

3. Conclusions

Plexins are a family of single-pass transmembrane receptors which have the ability to inhibit or potentiate tumor cell proliferation and invasiveness. Plexins function primarily as semaphorin receptors. Various plexins are expressed in tumor cells as well as in a variety of other cell types, which are recruited to the tumor microenvironment, such as endothelial cells. The final effects on tumor progression are, of course, an integration of all of these effects, but here we have only covered the direct effects of plexin-mediated signal transduction on the behavior of tumor cells. Interestingly, the effects that given semaphorins have on the behavior of tumor cells are strongly modulated by the association of their plexin and neuropilin receptors with additional cell surface molecules. For example, sema3A, which normally inhibits tumor cell invasiveness when signaling through its plexin-A1 receptor, induces tumor cell invasiveness following the association of its plexin-A1 receptor with cell surface-associated perlecan. It is likely that in addition to the known interactions that we have covered here, there are additional interactions that can also modulate plexin-mediated responses of tumor cells to semaphorins. The identification of such modulating interactions is likely to become the focus of future studies.

Author Contributions

S.T. and G.N. wrote reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by grant 188-16 from the Israel Science Foundation.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hota, P.K.; Buck, M. Plexin structures are coming: Opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell Mol. Life Sci. 2012, 69, 3765–3805. [Google Scholar]
  2. Luo, Y.; Raible, D.; Raper, J.A. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993, 75, 217–227. [Google Scholar]
  3. Takahashi, T.; Strittmatter, S.M. PlexinA1 Autoinhibition by the Plexin Sema Domain. Neuron 2001, 29, 429–439. [Google Scholar]
  4. Janssen, B.J.; Robinson, R.A.; Perez-Branguli, F.; Bell, C.H.; Mitchell, K.J.; Siebold, C.; Jones, E.Y. Structural basis of semaphorin-plexin signalling. Nature 2010, 467, 1118–1122. [Google Scholar]
  5. Nogi, T.; Yasui, N.; Mihara, E.; Matsunaga, Y.; Noda, M.; Yamashita, N.; Toyofuku, T.; Uchiyama, S.; Goshima, Y.; Kumanogoh, A.; et al. Structural basis for semaphorin signalling through the plexin receptor. Nature 2010, 467, 1123–1127. [Google Scholar] [CrossRef]
  6. Artigiani, S.; Barberis, D.; Fazzari, P.; Longati, P.; Angelini, P.; van de Loo, J.W.; Comoglio, P.M.; Tamagnone, L. Functional regulation of semaphorin receptors by proprotein convertases. J. Biol. Chem. 2003, 278, 10094–10101. [Google Scholar] [PubMed] [Green Version]
  7. Siebold, C.; Jones, E.Y. Structural insights into semaphorins and their receptors. Semin. Cell Dev. Biol. 2012, 24, 139–145. [Google Scholar] [CrossRef] [PubMed]
  8. Oinuma, I.; Ishikawa, Y.; Katoh, H.; Negishi, M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 2004, 305, 862–865. [Google Scholar] [PubMed]
  9. Oinuma, I.; Katoh, H.; Negishi, M. Molecular dissection of the semaphorin 4D receptor plexin-B1-stimulated R-Ras GTPase-activating protein activity and neurite remodeling in hippocampal neurons. J. Neurosci. 2004, 24, 11473–11480. [Google Scholar]
  10. Saito, Y.; Oinuma, I.; Fujimoto, S.; Negishi, M. Plexin-B1 is a GTPase activating protein for M-Ras, remodelling dendrite morphology. EMBO Rep. 2009, 10, 614–621. [Google Scholar]
  11. Wang, Y.; He, H.; Srivastava, N.; Vikarunnessa, S.; Chen, Y.B.; Jiang, J.; Cowan, C.W.; Zhang, X. Plexins Are GTPase-Activating Proteins for Rap and Are Activated by Induced Dimerization. Sci. Signal. 2012, 5, ra6. [Google Scholar] [PubMed] [Green Version]
  12. Uesugi, K.; Oinuma, I.; Katoh, H.; Negishi, M. Different requirement for Rnd GTPases of R-Ras GAP activity of plexin-C1 and plexin-D1. J. Biol. Chem. 2009, 284, 6743–6751. [Google Scholar] [PubMed] [Green Version]
  13. Tamagnone, L.; Artigiani, S.; Chen, H.; He, Z.; Ming, G.I.; Song, H.; Chedotal, A.; Winberg, M.L.; Goodman, C.S.; Poo, M.; et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99, 71–80. [Google Scholar]
  14. Tamagnone, L.; Comoglio, P.M. Signalling by semaphorin receptors: Cell guidance and beyond. Trends Cell Biol. 2000, 10, 377–383. [Google Scholar] [PubMed]
  15. Rohm, B.; Ottemeyer, A.; Lohrum, M.; Puschel, A.W. Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A. Mech. Dev. 2000, 93, 95–104. [Google Scholar] [PubMed]
  16. Hayashi, M.; Nakashima, T.; Taniguchi, M.; Kodama, T.; Kumanogoh, A.; Takayanagi, H. Osteoprotection by semaphorin 3A. Nature 2012, 485, 69–74. [Google Scholar] [CrossRef]
  17. Puschel, A.W. GTPases in semaphorin signaling. Adv. Exp. Med. Biol. 2007, 600, 12–23. [Google Scholar]
  18. Zanata, S.M.; Hovatta, I.; Rohm, B.; Puschel, A.W. Antagonistic effects of Rnd1 and RhoD GTPases regulate receptor activity in Semaphorin 3A-induced cytoskeletal collapse. J. Neurosci. 2002, 22, 471–477. [Google Scholar]
  19. Rajan, S.; Terman, J.R.; Reisler, E. MICAL-mediated oxidation of actin and its effects on cytoskeletal and cellular dynamics. Front. Cell Dev. Biol. 2023, 11, 1124202. [Google Scholar]
  20. Perrot, V.; Vazquez-Prado, J.; Gutkind, J.S. Plexin B regulates Rho through the guanine nucleotide exchange factors Leukemia-associated RhoGEF (LARG) and PDZ-RhoGEF. J. Biol. Chem. 2002, 278, 26111–26119. [Google Scholar]
  21. Oinuma, I.; Katoh, H.; Harada, A.; Negishi, M. Direct interaction of Rnd1 with Plexin-B1 regulates PDZ-RhoGEF-mediated Rho activation by Plexin-B1 and induces cell contraction in COS-7 cells. J. Biol. Chem. 2003, 278, 25671–25677. [Google Scholar]
  22. Swiercz, J.M.; Worzfeld, T.; Offermanns, S. Semaphorin 4D signaling requires the recruitment of phospholipase C gamma into the plexin-B1 receptor complex. Mol. Cell. Biol. 2009, 29, 6321–6334. [Google Scholar] [PubMed] [Green Version]
  23. Driessens, M.H.; Olivo, C.; Nagata, K.; Inagaki, M.; Collard, J.G. B plexins activate Rho through PDZ-RhoGEF. FEBS Lett. 2002, 529, 168–172. [Google Scholar] [PubMed] [Green Version]
  24. Worzfeld, T.; Swiercz, J.M.; Senturk, A.; Genz, B.; Korostylev, A.; Deng, S.; Xia, J.; Hoshino, M.; Epstein, J.A.; Chan, A.M.; et al. Genetic dissection of plexin signaling in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, 2194–2199. [Google Scholar] [PubMed]
  25. Shalaby, M.A.; Hampson, L.; Oliver, A.; Hampson, I. Identification of PlexinD1 and AHDC1 as a putative interactors for Tip-1 protein. Genes Genom. 2011, 33, 399–405. [Google Scholar]
  26. Kigel, B.; Rabinowicz, N.; Varshavsky, A.; Kessler, O.; Neufeld, G. Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood 2011, 118, 4285–4296. [Google Scholar]
  27. Takahashi, T.; Fournier, A.; Nakamura, F.; Wang, L.H.; Murakami, Y.; Kalb, R.G.; Fujisawa, H.; Strittmatter, S.M. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999, 99, 59–69. [Google Scholar]
  28. Giordano, S.; Corso, S.; Conrotto, P.; Artigiani, S.; Gilestro, G.; Barberis, D.; Tamagnone, L.; Comoglio, P.M. The Semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 2002, 4, 720–724. [Google Scholar]
  29. Conrotto, P.; Corso, S.; Gamberini, S.; Comoglio, P.M.; Giordano, S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004, 23, 5131–5137. [Google Scholar]
  30. Conrotto, P.; Valdembri, D.; Corso, S.; Serini, G.; Tamagnone, L.; Comoglio, P.M.; Bussolino, F.; Giordano, S. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105, 4321–4329. [Google Scholar]
  31. Peacock, J.W.; Takeuchi, A.; Hayashi, N.; Liu, L.; Tam, K.J.; Al, N.N.; Khazamipour, N.; Tombe, T.; Dejima, T.; Lee, K.C.; et al. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol. Med. 2018, 10, 219–238. [Google Scholar] [PubMed]
  32. Catalano, A.; Lazzarini, R.; Di, N.S.; Orciari, S.; Procopio, A. The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-kappaB to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells. Cancer Res. 2009, 69, 1485–1493. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Swiercz, J.M.; Kuner, R.; Offermanns, S. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J. Cell Biol. 2004, 165, 869–880. [Google Scholar] [PubMed]
  34. Casazza, A.; Finisguerra, V.; Capparuccia, L.; Camperi, A.; Swiercz, J.M.; Rizzolio, S.; Rolny, C.; Christensen, C.; Bertotti, A.; Sarotto, I.; et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J. Clin. Investig. 2010, 120, 2684–2698. [Google Scholar] [CrossRef] [Green Version]
  35. Casazza, A.; Kigel, B.; Maione, F.; Capparuccia, L.; Kessler, O.; Giraudo, E.; Mazzone, M.; Neufeld, G.; Tamagnone, L. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol. Med. 2012, 4, 234–250. [Google Scholar] [CrossRef]
  36. Franco, M.; Tamagnone, L. Tyrosine phosphorylation in semaphorin signalling: Shifting into overdrive. EMBO Rep. 2008, 9, 865–871. [Google Scholar]
  37. Toledano, S.; Nir-Zvi, I.; Engelman, R.; Kessler, O.; Neufeld, G. Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression. Int. J. Mol. Sci. 2019, 20, 556. [Google Scholar]
  38. Wei, L.; Li, H.; Tamagnone, L.; You, H. Semaphorins and Their Receptors in Hematological Malignancies. Front. Oncol. 2019, 9, 382. [Google Scholar]
  39. Bica, C.; Tirpe, A.; Nutu, A.; Ciocan, C.; Chira, S.; Gurzau, E.S.; Braicu, C.; Berindan-Neagoe, I. Emerging roles and mechanisms of semaphorins activity in cancer. Life Sci. 2023, 318, 121499. [Google Scholar]
  40. Kanth, S.M.; Gairhe, S.; Torabi-Parizi, P. The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation. Front. Immunol. 2021, 12, 672441. [Google Scholar]
  41. Kolodkin, A.L.; Levengood, D.V.; Rowe, E.G.; Tai, Y.T.; Giger, R.J.; Ginty, D.D. Neuropilin is a semaphorin III receptor. Cell 1997, 90, 753–762. [Google Scholar]
  42. Sabag, A.D.; Smolkin, T.; Mumblat, Y.; Ueffing, M.; Kessler, O.; Gloeckner, C.J.; Neufeld, G. The role of the plexin-A2 receptor in Sema3A and Sema3B signal transduction. J. Cell Sci. 2014, 127, 5240–5252. [Google Scholar] [PubMed] [Green Version]
  43. Guttmann-Raviv, N.; Shraga-Heled, N.; Varshavsky, A.; Guimaraes-Sternberg, C.; Kessler, O.; Neufeld, G. Semaphorin-3A and Semaphorin-3F Work Together to Repel Endothelial Cells and to Inhibit Their Survival by Induction of Apoptosis. J. Biol. Chem. 2007, 282, 26294–26305. [Google Scholar]
  44. Casazza, A.; Laoui, D.; Wenes, M.; Rizzolio, S.; Bassani, N.; Mambretti, M.; Deschoemaeker, S.; Van Ginderachter, J.A.; Tamagnone, L.; Mazzone, M. Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell 2013, 24, 695–709. [Google Scholar]
  45. Catalano, A.; Caprari, P.; Rodilossi, S.; Betta, P.; Castellucci, M.; Casazza, A.; Tamagnone, L.; Procopio, A. Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation. FASEB J. 2004, 18, 358–360. [Google Scholar] [PubMed] [Green Version]
  46. Tellman, T.V.; Cruz, L.A.; Grindel, B.J.; Farach-Carson, M.C. Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration. Int. J. Mol. Sci. 2021, 22, 3218. [Google Scholar] [PubMed]
  47. Staton, C.A.; Shaw, L.A.; Valluru, M.; Hoh, L.; Koay, I.; Cross, S.S.; Reed, M.W.; Brown, N.J. Expression of class 3 semaphorins and their receptors in human breast neoplasia. Histopathology 2011, 59, 274–282. [Google Scholar]
  48. Yamada, D.; Watanabe, S.; Kawahara, K.; Maeda, T. Plexin A1 signaling confers malignant phenotypes in lung cancer cells. Biochem. Biophys. Res. Commun. 2016, 480, 75–80. [Google Scholar] [CrossRef]
  49. Higgins, D.M.O.; Caliva, M.; Schroeder, M.; Carlson, B.; Upadhyayula, P.S.; Milligan, B.D.; Cheshier, S.H.; Weissman, I.L.; Sarkaria, J.N.; Meyer, F.B.; et al. Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas. BMC Cancer 2020, 20, 1213. [Google Scholar]
  50. Tian, T.V.; Tomavo, N.; Huot, L.; Flourens, A.; Bonnelye, E.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: Involvement of MMP9 and PLXNA2. Oncogene 2013, 33, 2204–2214. [Google Scholar]
  51. Yin, L.; Li, J.; Wang, J.; Pu, T.; Wei, J.; Li, Q.; Wu, B.J. MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling. Oncogene 2021, 40, 1362–1374. [Google Scholar] [PubMed]
  52. Shostak, K.; Zhang, X.; Hubert, P.; Goktuna, S.I.; Jiang, Z.; Klevernic, I.; Hildebrand, J.; Roncarati, P.; Hennuy, B.; Ladang, A.; et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat. Commun. 2014, 5, 5232. [Google Scholar] [PubMed] [Green Version]
  53. Toledano, S.; Sabag, A.D.; Ilan, N.; Liburkin-Dan, T.; Kessler, O.; Neufeld, G. Plexin-A2 enables the proliferation and the development of tumors from glioblastoma derived cells. Cell Death. Dis. 2023, 14, 41. [Google Scholar]
  54. Syed, V.; Zhang, X.; Lau, K.M.; Cheng, R.; Mukherjee, K.; Ho, S.M. Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene 2005, 24, 8128–8143. [Google Scholar]
  55. Ding, H.; Li, L.; Gu, B.; Ni, Y.; Chen, S. MicroRNA-564 inhibits the progression of non-small cell lung cancer via targeting plexin A4. Exp. Ther. Med. 2021, 21, 358. [Google Scholar] [PubMed]
  56. Zhang, C.; Qiao, H.; Guo, W.; Liu, Y.; Yang, L.; Liu, Y.; Jin, B.; Fu, M.; Wang, G.; Li, W. CD100-Plexin-B1 induces Epithelial-Mesenchymal Transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Lett. 2019, 455, 1–13. [Google Scholar]
  57. Li, C.; Wan, L.; Wang, P.; Guan, X.; Li, C.; Wang, X. Sema4D/Plexin-B1 promotes the progression of osteosarcoma cells by activating Pyk2-PI3K-AKT pathway. J. Musculoskelet. Neuronal Interact. 2021, 21, 577–583. [Google Scholar]
  58. Liu, B.; Gu, X.; Huang, T.; Luan, Y.; Ding, X. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Oncol. Rep. 2017, 37, 201–208. [Google Scholar]
  59. Ye, S.; Hao, X.; Zhou, T.; Wu, M.; Wei, J.; Wang, Y.; Zhou, L.; Jiang, X.; Ji, L.; Chen, Y.; et al. Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer 2010, 10, 611. [Google Scholar]
  60. Malik, M.F.A.; Riaz, S.K.; Waqar, S.H.; Haq, F.; Ye, L.; Jiang, W.G. Role of Plexin B1 in a Breast Cancer Cohort of Pakistani Patients and its Contribution Towards Cancer Metastasis as Indicated by an In Vitro Model. Anticancer Res. 2017, 37, 4483–4488. [Google Scholar]
  61. Argast, G.M.; Croy, C.H.; Couts, K.L.; Zhang, Z.; Litman, E.; Chan, D.C.; Ahn, N.G. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene 2009, 28, 2697–2709. [Google Scholar] [CrossRef] [Green Version]
  62. Jiang, C.; Javed, A.; Kaiser, L.; Nava, M.M.; Xu, R.; Brandt, D.T.; Zhao, D.; Mayer, B.; Fernández-Baldovinos, J.; Zhou, L.; et al. Mechanochemical control of epidermal stem cell divisions by B-plexins. Nat. Commun. 2021, 12, 1308. [Google Scholar] [CrossRef]
  63. Gurrapu, S.; Pupo, E.; Franzolin, G.; Lanzetti, L.; Tamagnone, L. Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Differ. 2018, 25, 1259–1275. [Google Scholar] [CrossRef] [Green Version]
  64. Le, A.P.; Huang, Y.; Pingle, S.C.; Kesari, S.; Wang, H.; Yong, R.L.; Zou, H.; Friedel, R.H. Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget 2015, 6, 7293–7304. [Google Scholar] [CrossRef] [Green Version]
  65. Yu, W.; Goncalves, K.A.; Li, S.; Kishikawa, H.; Sun, G.; Yang, H.; Vanli, N.; Wu, Y.; Jiang, Y.; Hu, M.G.; et al. Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin. Cell 2017, 171, 849–864. [Google Scholar] [CrossRef] [Green Version]
  66. Li, S.; Goncalves, K.A.; Lyu, B.; Yuan, L.; Hu, G.F. Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitors. Commun. Biol. 2020, 3, 26–0750. [Google Scholar] [CrossRef] [Green Version]
  67. Yang, H.; Yuan, L.; Ibaragi, S.; Li, S.; Shapiro, R.; Vanli, N.; Goncalves, K.A.; Yu, W.; Kishikawa, H.; Jiang, Y.; et al. Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival. Br. J. Cancer 2022, 127, 422–435. [Google Scholar] [CrossRef] [PubMed]
  68. Liang, Y.; Meng, K.; Qiu, R. Circular RNA Circ_0013958 Functions as a Tumor Promoter in Ovarian Cancer by Regulating miR-637/PLXNB2 Axis. Front. Genet. 2021, 12, 644451. [Google Scholar] [CrossRef]
  69. Brundu, S.; Napolitano, V.; Franzolin, G.; Lo, C.E.; Mastrantonio, R.; Sardo, G.; Cascardi, E.; Verginelli, F.; Sarnataro, S.; Gambardella, G.; et al. Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. EMBO Mol. Med. 2023, 15, e16104. [Google Scholar] [CrossRef] [PubMed]
  70. Li, X.; Law, J.W.; Lee, A.Y. Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton. Oncogene 2011, 31, 595–610. [Google Scholar] [PubMed] [Green Version]
  71. Saxena, S.; Prajapati, D.R.; Goel, P.; Tomar, B.; Hayashi, Y.; Atri, P.; Rachagani, S.; Grandgenett, P.M.; Hollingsworth, M.A.; Batra, S.K.; et al. Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer. Cancers 2021, 13, 818. [Google Scholar] [CrossRef]
  72. Kuhlmann, L.; Govindarajan, M.; Mejia-Guerrero, S.; Ignatchenko, V.; Liu, L.Y.; Grünwald, B.T.; Cruickshank, J.; Berman, H.; Khokha, R.; Kislinger, T. Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. J. Proteome Res. 2022, 21, 2224–2236. [Google Scholar] [CrossRef] [PubMed]
  73. Scott, G.A.; McClelland, L.A.; Fricke, A.F.; Fender, A. Plexin C1, A Receptor for Semaphorin 7A, Inactivates Cofilin and Is a Potential Tumor Suppressor for Melanoma Progression. J. Investig. Dermatol. 2009, 129, 954–963. [Google Scholar] [CrossRef] [Green Version]
  74. Zhao, X.; Wang, P.; Liu, J.; Zheng, J.; Liu, Y.; Chen, J.; Xue, Y. Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222. Mol. Ther. 2015, 23, 1899–1911. [Google Scholar] [CrossRef] [Green Version]
  75. Ma, B.; Herzog, E.L.; Lee, C.G.; Peng, X.; Lee, C.M.; Chen, X.; Rockwell, S.; Koo, J.S.; Kluger, H.; Herbst, R.S.; et al. Role of Chitinase 3-like-1 and Semaphorin 7A in Pulmonary Melanoma Metastasis. Cancer Res. 2014, 75, 487–496. [Google Scholar]
  76. Chen, J.; Liu, H.; Chen, J.; Sun, B.; Wu, J.; Du, C. PLXNC1 Enhances Carcinogenesis Through Transcriptional Activation of IL6ST in Gastric Cancer. Front. Oncol. 2020, 10, 33. [Google Scholar] [CrossRef] [Green Version]
  77. Luchino, J.; Hocine, M.; Amoureux, M.C.; Gibert, B.; Bernet, A.; Royet, A.; Treilleux, I.; Lecine, P.; Borg, J.P.; Mehlen, P.; et al. Semaphorin 3E Suppresses Tumor Cell Death Triggered by the Plexin D1 Dependence Receptor in Metastatic Breast Cancers. Cancer Cell 2013, 24, 673–685. [Google Scholar] [PubMed] [Green Version]
  78. Man, J.; Shoemake, J.; Zhou, W.; Fang, X.; Wu, Q.; Rizzo, A.; Prayson, R.; Bao, S.; Rich, J.N.; Yu, J.S. Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. Cell Rep. 2014, 9, 1812–1826. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  79. Maione, F.; Molla, F.; Meda, C.; Latini, R.; Zentilin, L.; Giacca, M.; Seano, G.; Serini, G.; Bussolino, F.; Giraudo, E. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J. Clin. Investig. 2009, 119, 3356–3372. [Google Scholar]
  80. Hanahan, D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315, 115–122. [Google Scholar] [CrossRef]
  81. Tomizawa, Y.; Sekido, Y.; Kondo, M.; Gao, B.; Yokota, J.; Roche, J.; Drabkin, H.; Lerman, M.I.; Gazdar, A.F.; Minna, J.D. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc. Natl. Acad. Sci. USA 2001, 98, 13954–13959. [Google Scholar] [PubMed]
  82. Tischoff, I.; Markwarth, A.; Witzigmann, H.; Uhlmann, D.; Hauss, J.; Mirmohammadsadegh, A.; Wittekind, C.; Hengge, U.R.; Tannapfel, A. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int. J. Cancer 2005, 115, 684–689. [Google Scholar] [CrossRef] [PubMed]
  83. Nair, P.N.; McArdle, L.; Cornell, J.; Cohn, S.L.; Stallings, R.L. High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genet. Cytogenet. 2007, 174, 100–110. [Google Scholar] [PubMed]
  84. Pyatnitskiy, M.; Karpov, D.; Poverennaya, E.; Lisitsa, A.; Moshkovskii, S. Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. PLoS ONE 2015, 10, e0142819. [Google Scholar]
  85. Xiang, X.; Zhang, X.; Huang, Q.L. Plexin A3 is involved in semaphorin 3F-mediated oligodendrocyte precursor cell migration. Neurosci. Lett. 2012, 530, 127–132. [Google Scholar] [CrossRef] [PubMed]
  86. Kotan, L.D.; Ternier, G.; Cakir, A.D.; Emeksiz, H.C.; Turan, I.; Delpouve, G.; Kardelen, A.D.; Ozcabi, B.; Isik, E.; Mengen, E.; et al. Loss-of-function variants in SEMA3F and PLXNA3 encoding semaphorin-3F and its receptor plexin-A3 respectively cause idiopathic hypogonadotropic hypogonadism. Genet. Med. 2021, 23, 1008–1016. [Google Scholar]
  87. Cheng, H.J.; Bagri, A.; Yaron, A.; Stein, E.; Pleasure, S.J.; Tessier-Lavigne, M. Plexin-a3 mediates semaphorin signaling and regulates the development of hippocampal axonal projections. Neuron 2001, 32, 249–263. [Google Scholar]
  88. Doci, C.L.; Mikelis, C.M.; Lionakis, M.S.; Molinolo, A.A.; Gutkind, J.S. Genetic identification of SEMA3F as an anti-lymphangiogenic metastasis suppressor gene in head and neck squamous carcinoma. Cancer Res. 2015, 75, 2937–2948. [Google Scholar]
  89. Bielenberg, D.R.; Hida, Y.; Shimizu, A.; Kaipainen, A.; Kreuter, M.; Kim, C.C.; Klagsbrun, M. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J. Clin. Investig. 2004, 114, 1260–1271. [Google Scholar] [CrossRef]
  90. Kessler, O.; Shraga-Heled, N.; Lange, T.; Gutmann-Raviv, N.; Sabo, E.; Baruch, L.; Machluf, M.; Neufeld, G. Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis. Cancer Res. 2004, 64, 1008–1015. [Google Scholar] [CrossRef] [Green Version]
  91. Suto, F.; Tsuboi, M.; Kamiya, H.; Mizuno, H.; Kiyama, Y.; Komai, S.; Shimizu, M.; Sanbo, M.; Yagi, T.; Hiromi, Y.; et al. Interactions between Plexin-A2, Plexin-A4, and Semaphorin 6A Control Lamina-Restricted Projection of Hippocampal Mossy Fibers. Neuron 2007, 53, 535–547. [Google Scholar] [PubMed]
  92. Haklai-Topper, L.; Mlechkovich, G.; Savariego, D.; Gokhman, I.; Yaron, A. Cis interaction between Semaphorin6A and Plexin-A4 modulates the repulsive response to Sema6A. EMBO J. 2010, 29, 2635–2645. [Google Scholar]
  93. Celus, W.; Oliveira, A.I.; Rivis, S.; Van Acker, H.H.; Landeloos, E.; Serneels, J.; Cafarello, S.T.; Van, H.Y.; Mastrantonio, R.; Köhler, A.; et al. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. Cancer Immunol. Res. 2022, 10, 126–141. [Google Scholar] [CrossRef]
  94. Huang, Y.; Tejero, R.; Lee, V.K.; Brusco, C.; Hannah, T.; Bertucci, T.B.; Junqueira, A.C.; Katsyv, I.; Kluge, M.; Foty, R.; et al. Plexin-B2 facilitates glioblastoma infiltration by modulating cell biomechanics. Commun. Biol. 2021, 4, 145. [Google Scholar]
  95. Fett, J.W.; Strydom, D.J.; Lobb, R.R.; Alderman, E.M.; Bethune, J.L.; Riordan, J.F.; Vallee, B.L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985, 24, 5480–5486. [Google Scholar] [CrossRef]
  96. Liu, Y.; Wu, C.; Wang, Y.; Wen, S.; Wang, J.; Chen, Z.; He, Q.; Feng, D. Loss of plexin-B3 in hepatocellular carcinoma. Exp. Ther. Med. 2015, 9, 1247–1252. [Google Scholar] [CrossRef] [Green Version]
  97. Liu, H.; Juo, Z.S.; Shim, A.H.; Focia, P.J.; Chen, X.; Garcia, K.C.; He, X. Structural Basis of Semaphorin-Plexin Recognition and Viral Mimicry from Sema7A and A39R Complexes with PlexinC1. Cell 2010, 142, 749–761. [Google Scholar] [CrossRef] [Green Version]
  98. Odabas, G.; Cetin, M.; Turhal, S.; Baloglu, H.; Sayan, A.E.; Yagci, T. Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma. Can. J. Gastroenterol. Hepatol. 2018, 2018, 4040787. [Google Scholar] [CrossRef] [Green Version]
  99. NazimTurhal, S.; Dogan, M.; Esendagli, G.; Artac, M.; Korkmaz, L.; Coskun, H.S.; Goker, E.; PerranYumuk, F.; Bilgetekin, I.; Kose, F.; et al. The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: A Turkish Oncology Group (TOG) Study. J. Gastrointest. Cancer 2021, 53, 356–362. [Google Scholar] [PubMed]
  100. Ni, Z.; Huang, C.; Zhao, H.; Zhou, J.; Hu, M.; Chen, Q.; Ge, B.; Huang, Q. PLXNC1: A Novel Potential Immune-Related Target for Stomach Adenocarcinoma. Front. Cell Dev. Biol. 2021, 9, 662707. [Google Scholar]
  101. Martinez, F.O.; Gordon, S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep. 2014, 6, 13. [Google Scholar]
  102. Roodink, I.; Raats, J.; Van Der, Z.B.; Verrijp, K.; Kusters, B.; Van Bokhoven, H.; Linkels, M.; de Waal, R.M.; Leenders, W.P. Plexin d1 expression is induced on tumor vasculature and tumor cells: A novel target for diagnosis and therapy? Cancer Res. 2005, 65, 8317–8323. [Google Scholar]
  103. Vivekanandhan, S.; Mukhopadhyay, D. Divergent roles of Plexin D1 in Cancer. Biochim. Biophys. Acta Rev. Cancer 2019, 1872, 103–110. [Google Scholar] [CrossRef]
  104. Gu, C.; Yoshida, Y.; Livet, J.; Reimert, D.V.; Mann, F.; Merte, J.; Henderson, C.E.; Jessell, T.M.; Kolodkin, A.L.; Ginty, D.D. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307, 265–268. [Google Scholar] [PubMed]
  105. Yang, W.J.; Hu, J.; Uemura, A.; Tetzlaff, F.; Augustin, H.G.; Fischer, A. Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis. EMBO Mol. Med. 2015, 20, 1267–1284. [Google Scholar]
  106. Smolkin, T.; Nir-Zvi, I.; Duvshani, N.; Mumblat, Y.; Kessler, O.; Neufeld, G. Complexes of plexin-A4 and plexin-D1 convey semaphorin-3C signals to induce cytoskeletal collapse in the absence of neuropilins. J. Cell Sci. 2018, 131, jcs208298. [Google Scholar]
  107. Mumblat, Y.; Kessler, O.; Ilan, N.; Neufeld, G. Full length semaphorin-3C functions as an inhibitor of tumor lymphangiogenesis and tumor metastasis. Cancer Res. 2015, 75, 2177–2186. [Google Scholar]
  108. Bassi, D.E.; Fu, J.; de Lopez, C.R.; Klein-Szanto, A.J. Proprotein convertases: “master switches” in the regulation of tumor growth and progression. Mol. Carcinog. 2005, 44, 151–161. [Google Scholar]
  109. Shalaby, M.A.; Hampson, L.; Oliver, A.; Hampson, I. Plexin d1: New potential biomarker for cervical cancer. J. Immunoass. Immunochem. 2012, 33, 223–233. [Google Scholar]
Cancers 15 04046 g001
Figure 1. The structure of plexins: The nine vertebrate plexins are subdivided into four type A, three type B, and one each of plexins C and D. Plexins are single-pass transmembrane receptors distinguished by the presence of a split cytoplasmic GTPase-activating protein (GAP) domain that binds small GTPases such as Rho and Rac1. The extracellular domains of all plexins contain a sema domain, PSI (Plexin, Semaphorin, Integrin) motifs, and immunoglobulin-plexin-transcription (IPT) glycine–proline (G–P)-rich motifs, which the plexins share with the tyrosine kinase receptors belonging to the MET tyrosine-kinase receptors family.
Figure 1. The structure of plexins: The nine vertebrate plexins are subdivided into four type A, three type B, and one each of plexins C and D. Plexins are single-pass transmembrane receptors distinguished by the presence of a split cytoplasmic GTPase-activating protein (GAP) domain that binds small GTPases such as Rho and Rac1. The extracellular domains of all plexins contain a sema domain, PSI (Plexin, Semaphorin, Integrin) motifs, and immunoglobulin-plexin-transcription (IPT) glycine–proline (G–P)-rich motifs, which the plexins share with the tyrosine kinase receptors belonging to the MET tyrosine-kinase receptors family.
Cancers 15 04046 g001
Cancers 15 04046 g002
Figure 2. Inhibition of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to inhibit tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. In the case of sema3A, neuropilin is required in addition to a type A plexin. The intracellular domain of plexin-D1 was found to associate with the nuclear orphan receptor NR4A1, which is depicted on a yellow background. This, in turn, induces apoptosis of the breast cancer cells. The references shown at the bottom of the panels direct to the relevant manuscripts.
Figure 2. Inhibition of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to inhibit tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. In the case of sema3A, neuropilin is required in addition to a type A plexin. The intracellular domain of plexin-D1 was found to associate with the nuclear orphan receptor NR4A1, which is depicted on a yellow background. This, in turn, induces apoptosis of the breast cancer cells. The references shown at the bottom of the panels direct to the relevant manuscripts.
Cancers 15 04046 g002
Cancers 15 04046 g003
Figure 3. Potentiation of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to promote tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexin or neuropilin/plexin complexes in the case of the class-3 semaphorins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. Modulators of plexin-mediated signal transduction, which interact with the plexins, such as the cell surface receptors MET, VEGFR2, and perlecan, are depicted. Other molecules that affect signal transduction by various plexins, such as angiogenin which functions as an alternative plexin-B2 ligand, and MAOA and KIAA1199, which functions as modulators of sema3C or sema3A signaling, are depicted on a yellow background. Double-headed arrows indicate association with additional cell surface receptors, such as various tyrosine-kinase receptors, which can be activated following the binding of various semaphorins to their plexin receptors to promote tumor cell proliferation and invasiveness. The references shown at the bottom of the panels direct to the relevant manuscripts.
Figure 3. Potentiation of tumor cell proliferation and invasiveness through plexin-mediated signal transduction. Shown are the effects of semaphorins that were found to promote tumor cell proliferation or tumor cell invasiveness following their binding to the indicated plexin or neuropilin/plexin complexes in the case of the class-3 semaphorins. Semaphorins that can both inhibit or promote tumor progression depending on specific interactions of their plexin receptors with additional proteins are shown on a red background. Modulators of plexin-mediated signal transduction, which interact with the plexins, such as the cell surface receptors MET, VEGFR2, and perlecan, are depicted. Other molecules that affect signal transduction by various plexins, such as angiogenin which functions as an alternative plexin-B2 ligand, and MAOA and KIAA1199, which functions as modulators of sema3C or sema3A signaling, are depicted on a yellow background. Double-headed arrows indicate association with additional cell surface receptors, such as various tyrosine-kinase receptors, which can be activated following the binding of various semaphorins to their plexin receptors to promote tumor cell proliferation and invasiveness. The references shown at the bottom of the panels direct to the relevant manuscripts.
Cancers 15 04046 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Toledano, S.; Neufeld, G. Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity. Cancers 2023, 15, 4046. https://doi.org/10.3390/cancers15164046

AMA Style

Toledano S, Neufeld G. Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity. Cancers. 2023; 15(16):4046. https://doi.org/10.3390/cancers15164046

Chicago/Turabian Style

Toledano, Shira, and Gera Neufeld. 2023. "Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity" Cancers 15, no. 16: 4046. https://doi.org/10.3390/cancers15164046

APA Style

Toledano, S., & Neufeld, G. (2023). Plexins as Regulators of Cancer Cell Proliferation, Migration, and Invasivity. Cancers, 15(16), 4046. https://doi.org/10.3390/cancers15164046

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop